Emactuzumab|1448221-67-7|(RG 7155; RO 5509554)-陌孚医药/Medlife

您当前的位置：

Emactuzumab (Synonyms: RG 7155; RO 5509554)

目录号: PL06067 纯度: ≥97%

CAS No. :1448221-67-7

商品编号	规格	价格	会员价
PL06067-1mg	1mg	¥5069.09	请登录
PL06067-5mg	5mg	¥11127.27	请登录
PL06067-10mg	10mg	¥17309.09	请登录
PL06067-50mg	50mg	询价	询价
PL06067-100mg	100mg	询价	询价

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Emactuzumab
英文名称	Emactuzumab
英文别名	Emactuzumab
Cas No.	1448221-67-7
包装储存	Please store the product under the recommended conditions in the Certificate of Analysis.

产品详情

Emactuzumab (RG 7155) 是一种特异性单克隆抗体，可抑制集落刺激因子 1 受体 (CSF1R) 的激活。Emactuzumab 对 CSF-1R 具有高亲和力，K_i 值为 0.2 nM，可阻断 CSF-1R 二聚化。Emactuzumab 可用于多种疾病的研究，如弥漫型腱鞘巨细胞瘤（dt-GCT）。

生物活性

Emactuzumab(RG 7155) is a specific monoclonal antibody that inhibits colonystimulating factor 1 receptor (CSF1R) activation. Emactuzumab has high affinity for CSF-1R with K i value of 0.2 nM to blocks CSF-1R dimerization. Emactuzumab can be used for the research of several diseases, such as diffuse-type tenosynovial giant cell tumour (dt-GCT) .

性状

Liquid

IC50 & Target[1][2]

IC50: 0.2 nM (CSF-1R)

体外研究(In Vitro)

Emactuzumab (RG 7155) binds to human and cynomolgus CSF-1R with high affinity (Kd = 0.2 nM) to blocks CSF-1R dimerization.
RG7155 (0-10 μg/mL, 7 days) potently inhibited the viability of CSF-1-differentiated macrophages with an IC50 of 0.3 nM by inducing cell death.
RG7155 (30 μg/mL, 6 days) induces cell death of in vitro-differentiated human M2-like macrophages. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Emactuzumab(RG 7155) (i.v.; 0.1、1、10、30 and 100 mg/kg; once) increases CSF-1 concentration in nonhuman primates’ peripheral blood.
RG7155 (i.v.; 0, 30, and 100 mg/kg; once weekly; for 2 weeks) depletes CSF-1RCD163 macrophages in vivo. has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

ClinicalTrial

参考文献

[1]. Philippe A Cassier, et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. Lancet Oncol. 2015 Aug;16(8):949-56.
[2]. Carola H Ries, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014 Jun 16;25(6):846-59.

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation